LBT Innovations (ASX:LBT) has recognised a non-cash impairment charge of A$13.4 million.

This impairment is associated with a full write-down of the A$13.4 million carrying value of the company’s intangible assets, which are tied to APAS® technology.

Alongside this, LBT Innovations also anticipates to recognise a non-cash write-off of around A$5.5 million in deferred tax assets for the present year.

LBT Innovations is a company focused on developing clinical and medical technology.